A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma
Enhancer RNAs (eRNAs) are intergenic long noncoding RNAs (lncRNAs) participating in the development of malignant cancers via targeting cancer-associated genes and immune checkpoints. Immune infiltration of the tumor microenvironment was positively associated with overall survival (OS) in lung adenoc...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2022/8069858 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849307126967566336 |
|---|---|
| author | Li Wang Shao-quan Zhou Yu Zhou Jia-xi Lu |
| author_facet | Li Wang Shao-quan Zhou Yu Zhou Jia-xi Lu |
| author_sort | Li Wang |
| collection | DOAJ |
| description | Enhancer RNAs (eRNAs) are intergenic long noncoding RNAs (lncRNAs) participating in the development of malignant cancers via targeting cancer-associated genes and immune checkpoints. Immune infiltration of the tumor microenvironment was positively associated with overall survival (OS) in lung adenocarcinoma (LUAD). In this study, we aimed to explore the clinical significance of PCBP1-AS1 in LUAD and developed a novel prognostic signature based on two eRNAs. Our team discovered that the expression of PCBP1-AS1 was distinctly downregulated in LUAD specimens compared with nontumor specimens. Lower PCBP1-AS1 expression was related to advanced clinical stages and poor prognosis. KEGG analysis unveiled that the coexpression genes of PCBP1-AS1 were involved in the regulation of several tumor-related pathways. In addition, remarkable associations were observed between the expression of PCBP1-AS1 and the levels of several immune cells. Then, we used PCBP1-AS1 and TBX5-AS1 to develop a prognostic model. Survival assays unveiled that patients with higher risk scores exhibited a shorter OS in contrast to patients with lower risk scores. In addition, multivariable Cox regressive analysis indicated that the risk score was an independent prediction factor in LUAD sufferers. The anticancer drug sensitivity analysis indicated that risk score had a positive relationship with several anticancer drugs. Taken together, our findings indicated PCBP1-AS1 as a function modulator in LUAD development. In addition, we constructed a robust immune-related eRNA signature which might be a clinical prognosis factor for LUAD patients. |
| format | Article |
| id | doaj-art-1d0301dc97ba4fa2afa3d539e81a890c |
| institution | Kabale University |
| issn | 2314-7156 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-1d0301dc97ba4fa2afa3d539e81a890c2025-08-20T03:54:51ZengWileyJournal of Immunology Research2314-71562022-01-01202210.1155/2022/8069858A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung AdenocarcinomaLi Wang0Shao-quan Zhou1Yu Zhou2Jia-xi Lu3Department of OncologyDepartment of RadiologyDepartment of Respiratory Critical Care MedicineDepartment of OncologyEnhancer RNAs (eRNAs) are intergenic long noncoding RNAs (lncRNAs) participating in the development of malignant cancers via targeting cancer-associated genes and immune checkpoints. Immune infiltration of the tumor microenvironment was positively associated with overall survival (OS) in lung adenocarcinoma (LUAD). In this study, we aimed to explore the clinical significance of PCBP1-AS1 in LUAD and developed a novel prognostic signature based on two eRNAs. Our team discovered that the expression of PCBP1-AS1 was distinctly downregulated in LUAD specimens compared with nontumor specimens. Lower PCBP1-AS1 expression was related to advanced clinical stages and poor prognosis. KEGG analysis unveiled that the coexpression genes of PCBP1-AS1 were involved in the regulation of several tumor-related pathways. In addition, remarkable associations were observed between the expression of PCBP1-AS1 and the levels of several immune cells. Then, we used PCBP1-AS1 and TBX5-AS1 to develop a prognostic model. Survival assays unveiled that patients with higher risk scores exhibited a shorter OS in contrast to patients with lower risk scores. In addition, multivariable Cox regressive analysis indicated that the risk score was an independent prediction factor in LUAD sufferers. The anticancer drug sensitivity analysis indicated that risk score had a positive relationship with several anticancer drugs. Taken together, our findings indicated PCBP1-AS1 as a function modulator in LUAD development. In addition, we constructed a robust immune-related eRNA signature which might be a clinical prognosis factor for LUAD patients.http://dx.doi.org/10.1155/2022/8069858 |
| spellingShingle | Li Wang Shao-quan Zhou Yu Zhou Jia-xi Lu A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma Journal of Immunology Research |
| title | A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma |
| title_full | A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma |
| title_fullStr | A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma |
| title_full_unstemmed | A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma |
| title_short | A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma |
| title_sort | two erna based signature can impact the immune status and predict the prognosis and drug sensitivity of lung adenocarcinoma |
| url | http://dx.doi.org/10.1155/2022/8069858 |
| work_keys_str_mv | AT liwang atwoernabasedsignaturecanimpacttheimmunestatusandpredicttheprognosisanddrugsensitivityoflungadenocarcinoma AT shaoquanzhou atwoernabasedsignaturecanimpacttheimmunestatusandpredicttheprognosisanddrugsensitivityoflungadenocarcinoma AT yuzhou atwoernabasedsignaturecanimpacttheimmunestatusandpredicttheprognosisanddrugsensitivityoflungadenocarcinoma AT jiaxilu atwoernabasedsignaturecanimpacttheimmunestatusandpredicttheprognosisanddrugsensitivityoflungadenocarcinoma AT liwang twoernabasedsignaturecanimpacttheimmunestatusandpredicttheprognosisanddrugsensitivityoflungadenocarcinoma AT shaoquanzhou twoernabasedsignaturecanimpacttheimmunestatusandpredicttheprognosisanddrugsensitivityoflungadenocarcinoma AT yuzhou twoernabasedsignaturecanimpacttheimmunestatusandpredicttheprognosisanddrugsensitivityoflungadenocarcinoma AT jiaxilu twoernabasedsignaturecanimpacttheimmunestatusandpredicttheprognosisanddrugsensitivityoflungadenocarcinoma |